Literature DB >> 17336987

Effect of a common X-linked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) on the occurrence of premature myocardial infarction and stenotic atherosclerosis requiring revascularization.

K Alfakih1, B Brown, R A Lawrance, P Warburton, A Maqbool, K Walters, N J Samani, S G Ball, A J Balmforth, A S Hall.   

Abstract

OBJECTIVES: To assess the association of the angiotensin II type 2 (AT2) receptor (-1332 G/A) gene polymorphism with premature coronary artery disease (CAD) and investigate for a further role in both myocardial infarction and predominantly stenotic atherosclerosis requiring revascularisation. METHODS AND
RESULTS: We investigated 885 families, which consisted of at least one sibling affected with premature CAD and at least one unaffected sibling. Genotyping of subjects was performed using a restriction enzyme digestion of an initial 310 bp PCR fragment that included the AT2 (-1332 G/A) locus. The mean age of the 1143 individuals affected by premature CAD at the time of event was 50.6+/-9.1 years. The genetic data were analyzed for these families using the X-linked sibling transmission disequilibrium test (XS-TDT). We observed significant evidence for an association for the AT2 (-1332 G) locus and premature CAD (p-exact value=0.028). This was driven by a highly significant result in men (p-exact value=0.005). We performed further analyses to investigate for an association with myocardial infarction (Group 1) and stenotic atherosclerosis that was of sufficient severity as to require revascularization (Group 2). We found an increase in the frequency of the G/GG genotype in both Groups 1 and 2, being most marked in Group 2 (XS-TDT, p-exact value=0.0134); logistic regression (p=0.033, OR 1.38; 95% CI of 1.212-1.507).
CONCLUSION: We have observed evidence of association between the X-linked AT2 (-1332 G/A) polymorphism and premature CAD with further evidence of a statistically significant association with stenotic atherosclerosis requiring revascularization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336987     DOI: 10.1016/j.atherosclerosis.2007.01.028

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

Review 1.  Genetics of the human renin angiotensin system.

Authors:  Xavier Jeunemaitre
Journal:  J Mol Med (Berl)       Date:  2008-04-29       Impact factor: 4.599

2.  Association of angiotensin II type I and type II receptor genes polymorphisms with the presence of premature coronary disease and metabolic syndrome.

Authors:  Tarek A Abd El-Aziz; Randa H Mohamed; Noha A Rezk
Journal:  Mol Biol Rep       Date:  2014-01-03       Impact factor: 2.316

Review 3.  Angiotensin II type-2 receptor-specific effects on the cardiovascular system.

Authors:  Ying Li; Xiao-Hui Li; Hong Yuan
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

Review 4.  Genetic variants of the Renin Angiotensin system: effects on atherosclerosis in experimental models and humans.

Authors:  Alan Daugherty; Aruna Poduri; Xiaofeng Chen; Hong Lu; Lisa A Cassis
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

Review 5.  What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

Authors:  Ian C Lawrance
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

6.  Genomewide association analysis of coronary artery disease.

Authors:  Nilesh J Samani; Jeanette Erdmann; Alistair S Hall; Christian Hengstenberg; Massimo Mangino; Bjoern Mayer; Richard J Dixon; Thomas Meitinger; Peter Braund; H-Erich Wichmann; Jennifer H Barrett; Inke R König; Suzanne E Stevens; Silke Szymczak; David-Alexandre Tregouet; Mark M Iles; Friedrich Pahlke; Helen Pollard; Wolfgang Lieb; Francois Cambien; Marcus Fischer; Willem Ouwehand; Stefan Blankenberg; Anthony J Balmforth; Andrea Baessler; Stephen G Ball; Tim M Strom; Ingrid Braenne; Christian Gieger; Panos Deloukas; Martin D Tobin; Andreas Ziegler; John R Thompson; Heribert Schunkert
Journal:  N Engl J Med       Date:  2007-07-18       Impact factor: 91.245

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.